Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
Permanent URI for this collectionhttps://hdl.handle.net/11147/9
Browse
13 results
Search Results
Review Citation - WoS: 9Citation - Scopus: 7Micrornas and Long Non-Coding Rnas as Novel Targets in Anti-Cancer Drug Development(Bentham Science Publishers, 2023) Çetinkaya, Melisa; Baran, YusufNon-coding RNAs comprise the majority of RNAs that have been transcribed from the human genome, and these non-coding RNAs have essential regulatory roles in the cellular processes. They have been discovered to influence the expression of the genes, including tumor-suppressive and oncogenes, that establish the non-coding RNAs as novel targets for anti-cancer drug development. Among non-coding RNAs, microRNAs have been extensively studied in terms of cancer biology, and some microRNA-based therapeutics have been reached in clinical studies. Even though most of the research regarding targeting non-coding RNAs for anti-cancer drug development focused on microRNAs, long non-coding RNAs have also started to gain importance as potential therapeutic targets for cancer therapy. In this chapter, the strategies and importance of targeting microRNAs and long non-coding RNAs will be described, along with the clinical studies that involve microRNA-based cancer therapeutics and preclinical studies that involve long non-coding RNA-based therapeutics. Finally, the delivery strategies that have great importance in the effective delivery of the non-coding RNA-based cancer therapeutics, hence the therapy's effectiveness, will be described.Conference Object Determination of Therapeutic Effects of Multifunctional Micelle-Based Nanocarriers on Breast Cancer Cells(Elsevier, 2021) Ulu, Gizem Tuğçe; Bayram, Nazende Nur; Abdulhadi, N.; Gurdap, S.; Isoglu, A.; Isoglu, S. D.; Baran, YusufBackground: Breast cancer is the most common and frequent cause of death in women in all types of cancer. Current treatment protocols do not provide a complete cure and targeting therapy can provide an important avenue for successful treatment of breast cancer. In this study, we aim to determine the therapeutic effects of the drug-conjugated carrier system with the conjugation of peptide sequence and antibody on HER2-positive breast cancer cells.Book Part Citation - Scopus: 86The Role of Mirna in Cancer: Pathogenesis, Diagnosis, and Treatment(Humana Press, 2022) Uzuner, Erez; Ulu, Gizem Tuğçe; Gürler, Sevim Beyza; Baran, YusufCancer is also determined by the alterations of oncogenes and tumor suppressor genes. These gene expressions can be regulated by microRNAs (miRNA). At this point, researchers focus on addressing two main questions: “How are oncogenes and/or tumor suppressor genes regulated by miRNAs?” and “Which other mechanisms in cancer cells are regulated by miRNAs?” In this work we focus on gathering the publications answering these questions. The expression of miRNAs is affected by amplification, deletion or mutation. These processes are controlled by oncogenes and tumor suppressor genes, which regulate different mechanisms of cancer initiation and progression including cell proliferation, cell growth, apoptosis, DNA repair, invasion, angiogenesis, metastasis, drug resistance, metabolic regulation, and immune response regulation in cancer cells. In addition, profiling of miRNA is an important step in developing a new therapeutic approach for cancer. © 2022, Springer Science+Business Media, LLC, part of Springer Nature.Conference Object Changes in Gene Expression Profiles in Response To Apigenin in Imatinib Sensitive and Resistant Chronic Myeloid Leukemia Cells(FERRATA STORTI FOUNDATION, 2013) Baran, Yusuf; Gökbulut, Aysun; Cincin, Zeynep; Çakmakoğlu, Bedia; Kozanoğlu, İlknur[No abstract available]Conference Object Determination of Cytotoxic and Apoptotic Effects of Caffeic Acid Phenethyl Ester and Gossypol in Combination With Fludarabine at a Molecular Level in Acute Lymphoblastic Leukemia Cells(Ferrata Storti Foundation, 2013) Baran, Yusuf; İskender, G.; Pişkin, Özden; Özcan, Mehmet Ali[No abstract available]Conference Object Diagnostic and Therapeutic Potentials of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Chronic Myeloid Leukemia Patients(Ferrata Storti Foundation, 2013) Baran, Yusuf; Yandım, Melis; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, Özden; Özcan, Mehmet Ali[No abstract available]Conference Object Immunologically Detection of Bcr/Abl Fusion Protein With Flow Cytometry in K562 Chronic Myeloid Leukemia Cells and Comparison With Rt-Pcr Results(Ferrata Storti Foundation, 2013) Kozanoğlu, İlknur; Aygün, B.; Boğa, I.; Cansun, C.; Üstündağ, N.; Baran, Yusuf; Özdoğu, Hakan[No abstract available]Conference Object Jak/Stat Signalling Pathway Genes in the Regulation of Tyrosine Kinase Inhibitors Induced and Clinical Process in Chronic Myeloid Leukemia Patients(Elsevier, 2014) Kiraz, Yağmur; Kartal Yandım, Melis; Kozanoğlu, İlknur; Özdoğu, Hakan; Pişkin, I.; Özcan, Mehmet Ali; Saydam, Göksel; Şahin, Fahri; Avcu, Ferit; Ural, Ali Uğur; Ünal, Ali; Baran, Yusuf[No abstract available]Conference Object Antiproliferative and Apoptotic Effects of Resveratrol on Chronic Lymphocytic Leukemia Cells(Ferrata Storti Foundation, 2012) Baran, Yusuf; Gökbulut, Aysun; Özcan, Mehmet Ali; Pişkin, Özden; Ünlü, Miray[No abstract available]Conference Object Effects of Placental Derived Mesenchymal Stem Cells on Experimental Asthma(Wiley, 2015) Micili, Cilaker S.; Sözmen, Çağlayan S.; Karaman, M.; Baran, Yusuf; Kartal Yandım, Melis; Kiraz, Yağmur; Karaman, O.[No abstract available]